Publication:
Beneficial effects of eprodisate (NC-503) for patients with amyloid A (AA) amyloidosis: Results of a 2-year, multi-center, randomized, placebo-controlled trial

Simple item page
dc.contributor.authorsBenson, M. D.; Dember, L. M.; Gorevic, P. D.; Livneh, A.; Merlini, G.; Direskeneli, H.; Hunter, J.; Ben Maiz, H.; Hauck, W.; Garceau, D.
dc.date.accessioned2022-03-12T15:59:40Z
dc.date.accessioned2026-01-10T18:06:08Z
dc.date.available2022-03-12T15:59:40Z
dc.date.issued2006
dc.identifier.doi10.14309/00000434-200609001-01168
dc.identifier.eissn1572-0241
dc.identifier.issn0002-9270
dc.identifier.urihttps://hdl.handle.net/11424/224477
dc.identifier.wosWOS:000240656102169
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofAMERICAN JOURNAL OF GASTROENTEROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleBeneficial effects of eprodisate (NC-503) for patients with amyloid A (AA) amyloidosis: Results of a 2-year, multi-center, randomized, placebo-controlled trial
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPageS455
oaire.citation.issue9
oaire.citation.startPageS455
oaire.citation.titleAMERICAN JOURNAL OF GASTROENTEROLOGY
oaire.citation.volume101

Files

Collections

Araştırma Çıktıları